Home

Haegarda cost

ICER to Use Aetion Observational RWE to Update ValueTakhzyro Cuts Rate of Hereditary Angioedema Attacks, Phase

HAEGARDA Cost Comparison - Find The Best HAEGARDA Price

  1. HAEGARDA Savings, Coupons and Information. | C1 INHIBITOR, HUMAN (C1 in HIB i ter, HYOO muhn) helps to prevent angioedema attacks.
  2. Through our revolutionary program, Prescription Hope can obtain Haegarda for individuals at the set price of $50.00 per month direct from the source
  3. The mean cost of on-demand therapy for six months among patients given Haegarda was $108,025, and it was $82,591 for those taking Takhzyro, a difference of $25,434 and considered not statistically different. On-demand therapies included Berinert by CSL Behring, and Kalbitor or Firazyr, both by Takeda

Haegarda (C1 Inhibitor) - $50 Per Month - Coupons & Cost

Haegarda's mean cost was nearly $227,000 vs. Takhzyro's more than $278,000 - a difference of $51,000 (22%). Additional, on-demand drug therapy is sometimes needed at event onset such as swelling of face, throat or intestines The report showed that all three therapies exceeded commonly cited thresholds for cost-effectiveness: from $50,000 to $150,000 per quality-adjusted life year (QALY) gained. QALY is a measure of disease burden, including the quality and quantity of life. Haegarda required the smallest price reduction (28%) to be within traditional thresholds. HAEGARDA® Helps Prevent Hereditary Angioedema (HAE) Attacks. 223 DAYS. 0 ATTACKS. * THE RIGHT THERAPY MATTERS HAEGARDA is the HAE therapy that reduces attacks by 95% †. * In a later analysis of 63 patients followed over an average of 1.5 years, the median time to first attack was 224 days difference in the mean cost of on-demand therapy, although Takhzyro averaged $25,500 less. • These real-world data suggest Haegarda may be lower cost than Takhzyro during the first 180 days of HAE prophylaxis treatment; however, the analysis consisted of a small sample size. It will be important to have longer follow-up of member Through HAEGARDA Connect SM, you can have a nurse come to your home to help you get comfortable with preparing and injecting your medicine, and to help you learn safe practices. This training is available at no cost to you at the start of your treatment. HAEGARDA nurses can train those diagnosed with HAE, parents, and/or caregivers

A decision is expected toward the end of the second quarter. While the HAE population is relatively small, treatment can add significant costs for payors. HAE treatments typically come with high price tags with a per-dose cost ranging from $3,117 to $6,800 TOP. This medicine is for infusion into a vein or under the skin. It is usually given by a health care professional in a hospital or clinic setting. If you get this medicine at home, you will be taught how to prepare and give this medicine. Use exactly as directed The Icer report released yesterday concluded that, with a net price tag of $16,500 per dose, prophylactic therapy with Takhzyro would cost a staggering $1m per quality-adjusted life year (QALY) gained. Shire's older HAE drug Cinryze outdid even this, costing $5.9m per QALY gained, according to Icer View side-by-side comparisons of medication uses, ratings, cost, side effects and interactions. Berinert C1 esterase inhibitor (human) Remove Berinert from your drug comparison. Haegarda C1 esterase inhibitor (human) Remove Haegarda from your drug comparison. Prescribed for Hereditary Angioedema. Berinert may also be used for purposes not. Haegarda is a brand-name prescription drug. It's FDA-approved to prevent sudden, painful swelling in people with hereditary angioedema (HAE). Haegarda can be used in adults and children ages 6.

Haegarda's mean cost was nearly $227,000 vs. Takhzyro's more than $278,000 - a difference of $51,000 (22%). Additional, on-demand drug therapy is sometimes needed at event onset such as swelling. The study evaluated the cost of the two therapies over a 6-month timeframe. Haegarda's mean cost was nearly $227,000 vs. Takhzyro's more than $278,000 - a difference of $51,000 (22%). Additional, on-demand drug therapy is sometimes needed at event onset such as swelling of face, throat or intestines Get free Haegarda coupons instantly and save up to 85%. See the cheapest pharmacy price and start saving on Haegarda today Costs. According to estimates on WellRx.com, the cost of Takhzyro and Haegarda will vary depending on your treatment plan. The actual price you'll pay for either drug also depends on your.

Angioedema Prophylactic Costs Unsustainable in US, Real

Haegarda is the first subcutaneous C1 esterase inhibitor designed to prevent angioedema attacks, and Shire sued, arguing that the CSL drug violates a patent on its own HAE candidate SHP616. Shire. The lowest price was $289. I searched the internet some more, I found this site, gave the pharmacy your card and the cost was $130. What a big saving, I can't thank this site enough. If you have a high deductible medical insurance (like me) or no insurance at all and you want to save money on your prescriptions, print a card For example, these drugs will achieve cost-effectiveness at a threshold of $150,000 per quality-adjusted life-year for a monthly baseline attack rate of 3.43 for Haegarda, 3.78 for Takhzyro, and 5.85 for Cinryze. TABLE 1 Health Care Sector Perspective Results for Cinryze, Haegarda, and Takhzyro Cost-Effectivenes HAEGARDA nurse will teach you how to prepare the medicine and how to safely and correctly self-administer it. Once you've been trained, you will have access to additional support from your nurse. This training program is provided through HAEGARDA Connect at no cost to you

Recent Prime Study Finds Hereditary Angioedema Drug

  1. Economic analyses assessing long-term cost-effectiveness found that all three treatments far exceed commonly cited thresholds of $50,000-$150,000 per quality-adjusted life year (QALY) gained, with $243,000 per QALY for Haegarda, $5,870,000 per QALY for Cinryze, and $1,020,000 per QALY for lanadelumab
  2. Haegarda Connect This program provides brand name medications at no or low cost: Provided by: CSL Behring: PO Box 61501 King of Prussia, PA 19406. TEL: 844-423-4273 FAX: 866-415-2162: Languages Spoken: English, Spanish, Others By Translation Service. Program Website : Program Applications and Form
  3. Haegarda. C1 esterase inhibitor, human. Complement C1 esterase inhibitor is a man-made form of a protein in blood that helps control swelling in the body. People with a condition called hereditary angioedema do not have enough of this protein. Hereditary angioedema can cause attacks of swelling and symptoms such as stomach problems..
  4. When evaluating the long-term value for money of Haegarda, the panel's majority vote was split evenly between low and intermediate value. All three prophylactic treatments, at current pricing, exceed commonly cited thresholds for cost-effectiveness
  5. Co-pay program eligibility for commercially insured patients to cover the cost of insurance co-pays for HAEGARDA at 100%, up to the program maximum; HAEGARDA bridge program, temporary assistance for those who experience a gap in insurance coverage; Contact HAEGARDA Connect today at 1-844-HAEGARDA (1-844-423-4273) from 8AM-8PM ET

Therapies Reduce HAE Attacks, but Cost Too Much, Review

Haegarda (C1 esterase inhibitor [human]) C1-esterase inhibitor protein: SC: Adolescents 12 years and over and adults: Takhzyro (lanadelumab-flyo [recombinant]) Kallikrein inhibitor: SC: Adolescents 12 years and over and adults: Annual preventive treatments cost more than $500,000 on average C-1 esterase, haegarda Injection, c-1 esterase inhibitor (human), Haegarda, 10 units K2 C9016 payment for both the acquisition cost and pharmacy overhead costs associated with the drug, biological or therapeutic radiopharmaceutical. In addition, in CY 2018, a single payment of AS Table 28: CADTH Exploratory Analyses - Inclusion of Haegarda as Comparator (Assuming Cost of Haegarda Is Equal to the Cost of Cinryze).. 84 Table 29: CADTH Exploratory Analyses - Alternative Dosing for Berinert..... 84 Table 30: CADTH Exploratory Analyses - Mild, Moderate and Severe Attacks. c-1 esterase inhibitor human (haegarda) 10 units 900 9.40 j0636 calcitriol per 0.1mcg 100 0.60 also for free standing dialysis centers j0637 caspofungin acetate 5mg 20 20.21 j0638 canakinumab 1mg 150 107.03 j0670 mepivacaine hcl per 10ml 10 1.96 j0690 cefazolin sodium 500mg 12 0.6

HAEGARDA® Helps Prevent Hereditary Angioedema (HAE) Attack

National Average Drug Acquisition Cost. We update the National Average Drug Acquisition Cost (NADAC) data and comparison data weekly. Each month we post new data, including findings from the previous month's survey and weekly price changes that have occurred before the release of the next month's NADAC data As expected, the FDA cleared Biocryst Pharmaceuticals Inc.'s oral, once daily Orladeyo (berotralstat, formerly known as BCX-7353) for the prevention of hereditary angioedema (HAE) attacks. Last month, Research Triangle Park, N.C.-based Biocryst, as part of its earnings report, said approvals of the compound, a kallikrein inhibitor evaluated by U.S. regulators without an advisory committee. Haegarda® and Takhzyro® 8 • Expected to be FDA approved December 3, 2020 Cost to Rx Benefits not known at this time Viltepso™ (Viltolarsen) Duchenne Muscular Dystrophy • Works at the cellular level • Price competitive to Vyondys 53 • FDA approved in August 2020 Cost to the medical facility is approximately $750,000 PPY for a 66 lb. Ingredient Cost $84 + Dispensing Fee +$1 Gross Cost $85 - Member Copay/Deductible -$25 Plan Cost $60 - Rebate -$6 Net Cost $54 BCBSVT $100-17% $83 +$0.50 $83.50-$25 $58.50 Walgreens $1.50 PBM Spread Margi

One wildcard could be cost - if CSL chooses to price Haegarda at a huge discount this could disrupt the market, Bernstein analysts note. The big question is how much of a mark CSL can make if it. Medi-Span Price Rx is the industry's leading online drug pricing reference and analytical tool designed to help meet the demanding requirements of healthcare businesses. It provides quick access to widely used Medi-Span drug pricing content, plus analysis tools to help you strengthen your business decisions. Watch Video Haegarda Connect This program provides brand name medications at no or low cost: Provided by: CSL Behring: PO Box 61501 King of Prussia, PA 19406. TEL: 844-423-4273 FAX: 866-415-2162: Languages Spoken: English, Spanish, Others By Translation Service. Program Website : Patient Assistance Application A Prescription Drug List (PDL) - also called a formulary - is a list of commonly used medications, organized into cost levels, called tiers. These costs are decided by your employer or health plan. View your PDL to learn what's covered by your plan

Subject: Haegarda Page: 4 of 4 Prior authorization is required to ensure the safe, clinically appropriate and cost-effective use of Haegarda while maintaining optimal therapeutic outcomes. References 1. Zuraw BL. Clinical practice. Hereditary angioedema. N Engl J Med. Sep 4 2008;359(10):1027-36.2. 2. Haegarda. [package insert] HAEGARDA is the first and only subcutaneous prophylactic HAE treatment approved for children 6 years of age and older. KING OF PRUSSIA, Pa., Sept. 28, 2020 /PRNewswire/ -- CSL Behring, a global. Medical Authorization Table. The medical Authorization Table is your best resource for viewing medical policies and criteria used by Wellmark. It is also your first stop in learning whether an authorization is required. Obtain approval in advance to help prevent delays and unexpected costs. Beginning April 1, 2020, Part 2 providers will need to.

Hereditary Angioedema (HAE) is an inherited genetic disorder that can affect the autoimmune system causing recurrent episodes of severe swelling, most commonly in the limbs, face, intestines and airway. The condition is a result of low levels or improper functioning of a protein called C1 inhibitor HAEGARDA is a subcutaneous C1 esterase inhibitor (C1-INH) therapy indicated for routine prophylaxis to prevent hereditary angioedema (HAE) attacks in adolescent and adult patients1. Hereditary angioedema (HAE) is a rare hereditary disease that manifests itself as unpredictable and often severe attacks of edema and/or abdominal pain. HAEGARDA is a human plasma-derived, purified, pasteurized, lyophilized concentrate of C1-INH to be reconstituted for S.C. administration. HAEGARDA is prepared from large pools of human plasma from U.S. donors. The potency of C1-INH is expressed in International Units (IU), which is related to the current WHO Standard for C1-INH products

Starting a HAEGARDA CSL Prescription HAEGARDA

  1. Haegarda Phase 3 COMPACT 16-week Crossover Study (n= 79) In a very high cost business such as IVIG the odds are stacked up against the little guy without a significant innovative advantage. That is the critical differentiator for BCRX. Not only would Orladeyo be the first the oral preventative therapy (other than androgens) and thereby out.
  2. HAEGARDA is the first and only subcutaneous preventive treatment option for HAE in the US. data from studies evaluating the reduction in use of rescue medications to treat breakthrough HAE attacks and potential cost offsets associated with the use of subcutaneous C1-inhibitor as long-term prophylaxis for HAE
  3. Find everything you need to know about Complement C1 Esterase Inhibitor (Haegarda), including what it is used for, warnings, reviews, side effects, and interactions. Learn more about Complement C1.
  4. Call 1-855-4KCENTRA. More Info on Kcentra Hotline. The trademarks marked ® are registered by CSL Limited or its affiliates or subsidiaries in one or more jurisdictions, unless indicated otherwise. Haegarda Connect, Berinert Connect, Privigen Connect, Hizentra Connect, Idelvion Connect, Afstyla Connect, Humate-P Connect, and Zemaira Connect are.
  5. Haegarda Vial Generic Name: C1 esterase inhibitor This medication is used to help prevent swelling and painful attacks caused by a certain inherited disease ( hereditary angioedema -HAE)
  6. istered, plasma-derived concentrate of C1-esterase inhibitor and the only subcutaneous therapy approved in the United States for routine prophylaxis to prevent HAE attack.
  7. Recent Prime Study Finds Hereditary Angioedema Drug Therapy Costs Are Unsustainable. Article Comments (0) FREE Breaking News Alerts from StreetInsider.com! E-mail Address

New Treatments, Added Costs CVS Health Payor Solution

  1. Whether you are just getting started on RUCONEST, or have been on therapy for a while, our goal is to ensure you have access to your prescribed RUCONEST therapy in the event of an attack. To learn more about RUCONEST SOLUTIONS, call 1-855-613-4HAE (4423). bPatients new to RUCONEST may be eligible for a free trial (up to 4 vials or 2 doses)
  2. Total annual cost of having and treating HAE in the USA was also assessed in this survey . The average annual cost per patient was $44,597. Cost varied depending on the severity of the disease ranging from $11,587 for mildly affected patients to $28,764 and $104,857, respectively, for those moderately or severely affected
  3. Haegarda in children less than 6 years of age has not been established. Persons who experience frequent and/or severe episodes may be candidates for prophylactic treatment (1-4). Prior authorization is required to ensure the safe, clinically appropriate and cost-effective use of Haegarda while maintaining optimal therapeutic outcomes
  4. HAEGARDA is a subcutaneous C1 esterase inhibitor (C1-INH) therapy indicated for routine prevention of Hereditary Angioedema (HAE) attacks in adolescent and adult patients. ^1 HAE patients have.
  5. d patients to always have acute.

Common Brand(s): Haegarda This medication is used to help prevent swelling and painful attacks caused by a certain inherited disease (hereditary angioedema-HAE). Most people with this disease have too little of a certain substance produced by your body (C1-esterase inhibitor). Some people with this disease have normal amounts of the substance. 3 (Figure 1). The Mix2Vial transfer device must be positioned completely vertical prior to penetrating the stopper closure. Figure 1. 2.emo R ve the plastic package and discard it (Figure 2) Generic name: C1-esterase inhibitor - subcutaneous injection. Brand name (s) Haegarda. Uses. This medication is used to help prevent swelling and painful attacks caused by a certain inherited disease (hereditary angioedema-HAE). Most people with this disease have too little of a certain substance produced by your body (C1-esterase inhibitor)

The clinical trial was a multicenter, double-blind, parallel group, placebo-controlled, dose-ranging study, which assessed the safety and efficacy of TAKHZYRO in 125 patients with HAE type I or II (≥12 years of age). Patients were randomized to receive TAKHZYRO 150 mg every 4 weeks (n=28), TAKHZYRO 300 mg every 4 weeks (n=29), TAKHZYRO 300 mg. Subject: Haegarda Page: 4 of 4 Prior authorization is required to ensure the safe, clinically appropriate and cost effective use of Haegarda while maintaining optimal therapeutic outcomes. References 1. Zuraw BL. Clinical practice. Hereditary angioedema. N Engl J Med. Sep 4 2008;359(10):1027-36.2. 2. Haegarda. [package insert] HAEGARDA targets the root cause of HAE by replacing deficient or dysfunctional natural C1-INH, restoring functional C1-INH levels to above 40 percent, which is proposed to reduce the risk for HAE. If experienced, these tend to have a Less Severe expression i. throat irritation. dizziness. reactions at the site of the injection

05/01/2019 provider news: Cost Estimator for providers available. As of May 2019, you have access to our Cost Estimator tool through the Provider Center 2019 Medicare Part D plan search by formulary drug - Providing detailed information on the Medicare Part D program for every state, including selected Medicare Part D plan features and costs organized by State. Sign-up for our free Medicare Part D Newsletter, Use the Online Calculators, FAQs or contact us through our Helpdesk -- Powered by Q1Group LL

2018 Medicare Part D plan search by formulary drug - Providing detailed information on the Medicare Part D program for every state, including selected Medicare Part D plan features and costs organized by State. Sign-up for our free Medicare Part D Newsletter, Use the Online Calculators, FAQs or contact us through our Helpdesk -- Powered by Q1Group LL CSL Behring offers an array of therapeutic support programs. We are here to help. Learn more today

What is Haegarda? - GoodR

  1. Average wholesale price data (AWP) are speculated to be $26,484 for each 2-mL vial, with an approximate annual cost of $688,584, excluding rebate or contractual PBM discounts. In comparison, the AWP for the complement C1 esterase inhibitor, Cinryze, is approximately $686,400 per year, while Haegarda has an annual AWP of $586,560, depending on.
  2. HAEGARDA ®, increased 16%2 resulted in significant opportunity costs to our standard business and manufacturing operations and the re-prioritisation of some R&D projects. Subsequently, there will be an increase in operations and R&D spend in the second half as we restart projects an
  3. GENOTROPIN COMES WITH SAVINGS AND RESOURCE OPTIONS GENOTROPIN Copay Program One simple plan covers copays and deductibles. Plus, patients are automatically re-enrolled January 1 of each year. To enroll, contact your Patient Care Consultant (PCC) at 1-800-645-1280 Eligible, commercially insured patients may pay as low as $0 per prescription* Offering savings up to $5,000 per year Of eligible.
  4. Haegarda Approved for Pediatric Use . In a press release dated Sept. 28, 2020, CSL Behring revealed that the indication for its Haegarda ® (C1 esterase inhibitor subcutaneous [human]) was extended by the FDA to patients who are as young as six years old. It is indicated for routine prophylaxis to prevent attacks of hereditary angioedema (HAE)

They estimated the annual per-patient cost of HAE to be $42,000 for the average patient, with annual costs estimated at $14,000 for patients with mild attacks, $27,000 for patients with moderate. HAEGARDA is the first and only subcutaneous prophylactic HAE treatment approved for children 6 years of age and older. KING OF PRUSSIA, Pa., Sept. 28, 2020 /PRNewswire/ -- CSL Behring, a global biotherapeutics leader, announced today that the U.S. Food and Drug Administration (FDA) has approved an expanded indication for HAEGARDA ® (C1 Esterase Inhibitor Subcutaneous [Human]) for routine. Health NAVIGATION Navigating Health Care Questions or concerns? Please contact: Blue Cross and Blue Shield of Vermont P.O. Box 186 Montpelier, VT 05601-018 Register for MyBlue. MyBlue offers online tools, resources and services for Blue Cross Blue Shield of Arizona Members, contracted brokers/consultants, healthcare professionals, and group benefit administrators. 24/7 online access to account transactions and other useful resources, help to ensure that your account information is available to you any time of the day or night

A prescriber can submit a Prior Authorization Form to Navitus via U.S. Mail or fax, or they can contact our call center to speak to a Prior Authorization Specialist. The request processes as quickly as possible once all required information is together. If the submitted form contains complete information, it will be compared to the criteria for. The ICER used data from three pivotal phase III randomised trials to assess the clinical effectiveness, tolerability and safety of lanadelumab and two C1-esterase inhibitors (C1-INHs; Cinryze and Haegarda) for long-term prophylaxis of HAE type 1 and type 2, compared with no prophylaxis anti-fibrinolytic agents, or Haegarda. If the clinical criteria for Takhzyro are met, initial PA requests may be approved for up to 183 days. Renewal PA requests for Takhzyro may be listed on the Select High Cost, Orphan, and Accelerated Drugs data table. The following clinical criteria must be met and documented for approval o 1-Member cost share payments for these medications, whether made by you, your plan or a manufacturer copay assistance program, do not count towards the plan's outof pocket maximum. EES with Fertility and with HIV Specialty Drug List March 2021 Medications listed below are covered under the PrudentRx Progra

Haegarda should not be used in individuals who have experienced life-threatening hypersensitivity reactions, including anaphylaxis, to a C1-INH preparation or its inactive ingredients. The dosage of Haegarda is 60 International Units per kg body weight twice-weekly (every 3 or 4 days). Haegarda is not indicated for treatment of acute HAE attacks Haegarda (C1 esterase inhibitor) is a plasma-derived concentrate of C1 esterase inhibitor. It raises your working C1 inhibitor level. It is used to prevent an HAE attack in adolescents and adults

Cost-effectiveness doubts could hit Shire's Takhzyro

The cost of producing several of these major products is low and the broker expects material expansion in the margins for Behring. Regarding FY19, UBS believes expansion of Idelvion and Haegarda sales, and a continued shift to Privigen and Hizentra in immunoglobulin from Carimune, will support another year of robust earnings, even with a more. The clinical trials for Haegarda and Takhzyro included patients with a pretreatment attack rate of 3.3 and 3.5 attacks per month. The clinical trials for Cinryze required patients to have at least 2 attacks per month. The Institute for Clinical and Economic Review (ICER) completed a cost-comparison review o Where applicable, the plan may compare the cost- effectiveness of alternative services, settings or supplies when determining least intensivesetting. 1. Haegarda® (C1 Esterase Inhibitor Subcutaneous (human)) J0599 . Injection, c-1 esterase inhibitor (human), (Haegarda), 10 units . Hemlibra® (emicizumab-kxwh In its latest endeavor, ICER plans to examine the coverage policies — including cost sharing, clinical eligibility criteria, prior authorization processes and step therapy protocols — of 15 U.S. commercial payers to determine if they provide fair patient access to 28 commonly used prescription drugs (as assessed by ICER according to a. The average annual cost of 61 specialty drugs widely used for treating chronic conditions reached roughly $79,000. The stakes are high for both the members and plan sponsors. Data-driven clinical oversight is a proven mechanism to ensure appropriateness and Rx plan sustainability

Berinert vs Haegarda Comparison - Drugs

A six-month placebo-controlled trial showed a 44% reduction in attacks for Orladeyo,® compared to reductions of 87% and 84% for Takhzyro® and Haegarda,® respectively, in separate placebo-controlled trials. 1,2,3 However, a more complete data set became available in June 2020, showing that efficacy of Orladeyo® improved to 66% when. Hereditary angioedema (HAE) is a rare autosomal dominant disease characterized by episodic unpredictable swelling. The United States Hereditary Angioedema Association Medical Advisory Board (US HAEA MAB) published guidelines for HAE management in 2013. 1 In the 6 years since that publication, considerable progress has been made in our classification and understanding of HAE as well as major. Hereditary angioedema (HAE) is a disease characterized by recurrent episodes (also called attacks) of severe swelling of the skin and mucous membranes. The age at which attacks begin varies, but most people have their first one in childhood or adolescence. The frequency of attacks usually increases after puberty FDA Approved 46 Novel Drugs in 2017. In 2016 we saw 22 brand-new novel drugs hit the market. This year the FDA has approved 46 novel drugs. A novel drug is an innovative product with a chemical structure that has never been FDA approved before and usually meets a previously unmet medical need The additional costs may be significant. If your doctor feels there is a medical Haegarda® Ruconest® Idiopathic pulmonary . fibrosis . Esbriet® Ofev® Immune globulin . Cuvitru™ Gammagard® liquid . Gammaked™ Gamunex C® Hizentra™ Hyqvia . Inflammatory diseases

erinert, Ruconest, Haegarda) Icatibant (Firazyr) Lanadelumab-flyo (Takhzyro)-mediated Amyloidosis Inotersen (Tegsedi) (Triumeq) Atazanavir (Reyataz) Atazanavir / obicistat (Evotaz) (iktarvy) Members with an out-of-network benefit may use other pharmacies, but cost shares may be higher. Formulary status and limitations apply Prior authorization is required to ensure the safe, clinically appropriate and cost effective use of Orladeyo (berotralstat) while maintaining optimal therapeutic outcomes. References 1. Cinryze Prescribing Information. Shire ViroPharma, Inc. Lexington, MA. June 2018. 2. Haegarda Prescribing Information. CSL Behring, LLC. Kankakee, IL. HAEGARDA Monographs. C1 inhibitor, human is a plasma-derived concentrate of C1 esterase inhibitor indicated for the prevention and treatment of angioedema attacks in patients with hereditary angioedema (HAE). Hereditary angioedema is a rare genetic disorder that presents as acute, recurrent attacks of soft tissue skin swelling, abdominal pain. Hereditary Angioedema, or HAE, is a key growth franchise for Shire. On May 18, 2017, Shire has announced strong Phase III results for SHP643 (lanadelumab) from the HELP study